Gene therapy for the prevention of vein graft disease

Roger, 2012, Executive summary: heart disease and stroke statistics–2012 update: a report from the American Heart Association, Circulation, 125, 188, 10.1161/CIR.0b013e3182456d46 Bittl, 1996, Advances in coronary angioplasty, N Engl J Med, 335, 1290, 10.1056/NEJM199610243351707 Haider, 2006, Two-year outcome with preferential use of infrainguinal angioplasty for critical ischemia, J Vasc Surg, 43, 504, 10.1016/j.jvs.2005.11.016 Adam, 2005, Bypass versus angioplasty in severe ischaemia of the leg (BASIL): multicentre, randomised controlled trial, Lancet, 366, 1925, 10.1016/S0140-6736(05)67704-5 Goodney, 2009, National trends in lower extremity bypass surgery, endovascular interventions, and major amputations, J Vasc Surg, 50, 54, 10.1016/j.jvs.2009.01.035 Hata, 2007, What is the optimal management for preventing saphenous vein graft diseases?: early results of intravascular angioscopic assessment, Circ J, 71, 286, 10.1253/circj.71.286 Parang, 2009, Coronary vein graft disease: pathogenesis and prevention, Can J Cardiol, 25, e57, 10.1016/S0828-282X(09)70486-6 Conte, 2005, Design and rationale of the PREVENT III clinical trial: edifoligide for the prevention of infrainguinal vein graft failure, Vasc Endovascular Surg, 39, 15, 10.1177/153857440503900102 Roger, 2011, Heart disease and stroke statistics–2011 update: a report from the American Heart Association, Circulation, 123, e18, 10.1161/CIR.0b013e3182009701 1997, The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. The Post Coronary Artery Bypass Graft Trial Investigators, N Engl J Med, 336, 153, 10.1056/NEJM199701163360301 Shah, 2008, Intensive lipid-lowering with atorvastatin for secondary prevention in patients after coronary artery bypass surgery, J Am Coll Cardiol, 51, 1938, 10.1016/j.jacc.2007.12.054 Domanski, 2008, Pleiotropic effect of lovastatin, with and without cholestyramine, in the post coronary artery bypass graft (Post CABG) trial, Am J Cardiol, 102, 1023, 10.1016/j.amjcard.2008.05.053 Fitzgibbon, 1996, Coronary bypass graft fate and patient outcome: angiographic follow-up of 5,065 grafts related to survival and reoperation in 1,388 patients during 25 years, J Am Coll Cardiol, 28, 616, 10.1016/0735-1097(96)00206-9 Alexander, 2005, Efficacy and safety of edifoligide, an E2F transcription factor decoy, for prevention of vein graft failure following coronary artery bypass graft surgery: PREVENT IV: a randomized controlled trial, JAMA, 294, 2446, 10.1001/jama.294.19.2446 Favaloro, 1968, Saphenous vein autograft replacement of severe segmental coronary artery occlusion: operative technique, Ann Thorac Surg, 5, 334, 10.1016/S0003-4975(10)66351-5 Eltzschig, 2004, Vascular ischaemia and reperfusion injury, British Medical Bulletin, 70, 71, 10.1093/bmb/ldh025 Shuvaev, 2011, Targeted modulation of reactive oxygen species in the vascular endothelium, J Control Release, 153, 56, 10.1016/j.jconrel.2011.03.022 Dashwood, 2012, ‘No-touch’ saphenous vein harvesting improves graft performance in patients undergoing coronary artery bypass surgery: A journey from bedside to bench, Vascul Pharmacol, 10.1016/j.vph.2012.07.008 Sepehripour, 2011, Does a 'no-touch' technique result in better vein patency?, Interact Cardiovasc Thorac Surg, 13, 626, 10.1510/icvts.2011.281998 Davies, 1993, The integrity of experimental vein graft endothelium–implications on the etiology of early graft failure, Eur J Vasc Surg, 7, 156, 10.1016/S0950-821X(05)80756-X Cheng, 2007, Mechanical stretch simulates proliferation of venous smooth muscle cells through activation of the insulin-like growth factor-1 receptor, Arterioscler Thromb Vasc Biol, 27, 1744, 10.1161/ATVBAHA.107.147371 Song, 2007, Emerging role of IGF-1R in stretch-induced neointimal hyperplasia in venous grafts, Arterioscler Thromb Vasc Biol, 27, 1679, 10.1161/ATVBAHA.107.148189 Kozai, 2005, Statins prevent pulsatile stretch-induced proliferation of human saphenous vein smooth muscle cells via inhibition of Rho/Rho-kinase pathway, Cardiovasc Res, 68, 475, 10.1016/j.cardiores.2005.07.002 Tanaka, 1993, Sustained activation of vascular cells and leukocytes in the rabbit aorta after balloon injury, Circulation, 88, 1788, 10.1161/01.CIR.88.4.1788 Springer, 1994, Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm, Cell, 76, 301, 10.1016/0092-8674(94)90337-9 Lee, 2004, Molecular and cellular basis of restenosis after percutaneous coronary intervention: the intertwining roles of platelets, leukocytes, and the coagulation–fibrinolysis system, J Pathol, 203, 861, 10.1002/path.1598 Huynh, 2001, Local treatment with recombinant tissue factor pathway inhibitor reduces the development of intimal hyperplasia in experimental vein grafts, J Vasc Surg, 33, 400, 10.1067/mva.2001.111989 Davies, 1994, Pathobiology of intimal hyperplasia, Br J Surg, 81, 1254, 10.1002/bjs.1800810904 Schwartz, 1997, Smooth muscle migration in atherosclerosis and restenosis, J Clin Invest, 100, S87 Mitra, 2006, Cellular, molecular and immunological mechanisms in the pathophysiology of vein graft intimal hyperplasia, Immunol Cell Biol, 84, 115, 10.1111/j.1440-1711.2005.01407.x Lardenoye, 2002, Accelerated atherosclerosis and calcification in vein grafts: a study in APOE*3 Leiden transgenic mice, Circ Res, 91, 577, 10.1161/01.RES.0000036901.58329.D7 Wan, 2012, Vein graft failure: current clinical practice and potential for gene therapeutics, Gene Ther, 19, 630, 10.1038/gt.2012.29 Hata, 2005, Modulation of phosphatidylinositol 3-kinase signaling reduces intimal hyperplasia in aortocoronary saphenous vein grafts, J Thorac Cardiovasc Surg, 129, 1405, 10.1016/j.jtcvs.2004.11.048 Santel, 2006, A novel siRNA-lipoplex technology for RNA interference in the mouse vascular endothelium, Gene Ther, 13, 1222, 10.1038/sj.gt.3302777 Miyake, 2006, Inhibitory effects of NFκB decoy oligodeoxynucleotides on neointimal hyperplasia in a rabbit vein graft model, J Mol Cell Cardiol, 41, 431, 10.1016/j.yjmcc.2006.04.006 Morishita, 1995, A gene therapy strategy using a transcription factor decoy of the E2F binding site inhibits smooth muscle proliferation in vivo, Proc Natl Acad Sci U S A, 92, 5855, 10.1073/pnas.92.13.5855 Sun, 2012, Preventing intimal thickening of vein grafts in vein artery bypass using STAT-3 siRNA, J Transl Med, 10, 2, 10.1186/1479-5876-10-2 Mann, 1999, Ex-vivo gene therapy of human vascular bypass grafts with E2F decoy: the PREVENT single-centre, randomised, controlled trial, Lancet, 354, 1493, 10.1016/S0140-6736(99)09405-2 Panyam, 2003, Biodegradable nanoparticles for drug and gene delivery to cells and tissue, Adv Drug Deliv Rev, 55, 329, 10.1016/S0169-409X(02)00228-4 Desai, 1997, The mechanism of uptake of biodegradable microparticles in Caco-2 cells is size dependent, Pharmaceut Res, 14, 1568, 10.1023/A:1012126301290 Desai, 1996, Gastrointestinal uptake of biodegradable microparticles: effect of particle size, Pharmaceut Res, 13, 1838, 10.1023/A:1016085108889 Panyam, 2002, Rapid endo-lysosomal escape of poly(DL-lactide-co-glycolide) nanoparticles: implications for drug and gene delivery, FASEB J, 16, 1217, 10.1096/fj.02-0088com Guzman, 1996, Local intraluminal infusion of biodegradable polymeric nanoparticles. A novel approach for prolonged drug delivery after balloon angioplasty, Circulation, 94, 1441, 10.1161/01.CIR.94.6.1441 Labhasetwar, 1999, Gene transfection using biodegradable nanospheres: results in tissue culture and a rat osteotomy model, Colloid Surface B, 16, 281, 10.1016/S0927-7765(99)00079-X Hanafusa, 1995, Biodegradable plate fixation of rabbit femoral shaft osteotomies. A comparative study, Clin Orthopaed Relat Res, 262 Davda, 2002, Characterization of nanoparticle uptake by endothelial cells, International journal of pharmaceutics, 233, 51, 10.1016/S0378-5173(01)00923-1 Cohen-Sacks, 2002, Novel PDGFβR antisense encapsulated in polymeric nanospheres for the treatment of restenosis, Gene Ther, 9, 1607, 10.1038/sj.gt.3301830 Walther, 2000, Viral vectors for gene transfer: a review of their use in the treatment of human diseases, Drugs, 60, 249, 10.2165/00003495-200060020-00002 Schulick, 1997, Established immunity precludes adenovirus-mediated gene transfer in rat carotid arteries. Potential for immunosuppression and vector engineering to overcome barriers of immunity, J Clin Invest, 99, 209, 10.1172/JCI119149 Yang, 1994, Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy, Proc Natl Acad Sci U S A, 91, 4407, 10.1073/pnas.91.10.4407 Channon, 1998, Acute host-mediated endothelial injury after adenoviral gene transfer in normal rabbit arteries: impact on transgene expression and endothelial function, Circ Res, 82, 1253, 10.1161/01.RES.82.12.1253 Newman, 1995, Adenovirus-mediated gene transfer into normal rabbit arteries results in prolonged vascular cell activation, inflammation, and neointimal hyperplasia, J Clin Invest, 96, 2955, 10.1172/JCI118367 Brooks, 2004, Transcriptional silencing is associated with extensive methylation of the CMV promoter following adenoviral gene delivery to muscle, J Gene Med, 6, 395, 10.1002/jgm.516 Doerfler, 1989, Promoter inactivation or inhibition by sequence-specific methylation and mechanisms of reactivation, Cell Biophys, 15, 21, 10.1007/BF02991576 Groudine, 1981, Chromatin structure of endogenous retroviral genes and activation by an inhibitor of DNA methylation, Nature, 292, 311, 10.1038/292311a0 Guzman, 1993, Efficient gene transfer into myocardium by direct injection of adenovirus vectors, Circ Res, 73, 1202, 10.1161/01.RES.73.6.1202 Kochanek, 1996, A new adenoviral vector: Replacement of all viral coding sequences with 28 kb of DNA independently expressing both full-length dystrophin and beta-galactosidase, Proc Natl Acad Sci U S A, 93, 5731, 10.1073/pnas.93.12.5731 Parks, 1996, A helper-dependent adenovirus vector system: removal of helper virus by Cre-mediated excision of the viral packaging signal, Proc Natl Acad Sci U S A, 93, 13565, 10.1073/pnas.93.24.13565 Wen, 2004, Improved vascular gene transfer with a helper-dependent adenoviral vector, Circulation, 110, 1484, 10.1161/01.CIR.0000141574.78032.A9 Marshall, 1999, Gene therapy death prompts review of adenovirus vector, Science, 286, 2244, 10.1126/science.286.5448.2244 Lehrman, 1999, Virus treatment questioned after gene therapy death, Nature, 401, 517, 10.1038/43977 Wasala, 2011, The evolution of heart gene delivery vectors, J Gene Med, 13, 557, 10.1002/jgm.1600 Eslami, 2000, Gene delivery to in situ veins: differential effects of adenovirus and adeno-associated viral vectors, J Vasc Surg, 31, 1149, 10.1067/mva2000.106951 Gruchala, 2004, Gene transfer into rabbit arteries with adeno-associated virus and adenovirus vectors, J Gene Med, 6, 545, 10.1002/jgm.535 Svensson, 1999, Efficient and stable transduction of cardiomyocytes after intramyocardial injection or intracoronary perfusion with recombinant adeno-associated virus vectors, Circulation, 99, 201, 10.1161/01.CIR.99.2.201 Wagner, 1998, Efficient and persistent gene transfer of AAV-CFTR in maxillary sinus, Lancet, 351, 1702, 10.1016/S0140-6736(05)77740-0 Kaplitt, 2007, Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial, Lancet, 369, 2097, 10.1016/S0140-6736(07)60982-9 Finn, 2012, The efficacy and the risk of immunogenicity of FIX Padua (R338L) in hemophilia B dogs treated by AAV muscle gene therapy, Blood, 120, 4521, 10.1182/blood-2012-06-440123 Pankajakshan, 2012, Successful transfection of genes using AAV-2/9 vector in swine coronary and peripheral arteries, J Surg Res, 175, 169, 10.1016/j.jss.2011.02.032 Work, 2006, Vascular bed-targeted in vivo gene delivery using tropism-modified adeno-associated viruses, Mol Ther, 13, 683, 10.1016/j.ymthe.2005.11.013 Work, 2004, Development of efficient viral vectors selective for vascular smooth muscle cells, Mol Ther, 9, 198, 10.1016/j.ymthe.2003.11.006 Nicklin, 2001, Efficient and selective AAV2-mediated gene transfer directed to human vascular endothelial cells, Mol Ther, 4, 174, 10.1006/mthe.2001.0424 McCarty, 2008, Self-complementary AAV vectors; advances and applications, Mol Ther, 16, 1648, 10.1038/mt.2008.171 Cefai, 2005, Multiply attenuated, self-inactivating lentiviral vectors efficiently transduce human coronary artery cells in vitro and rat arteries in vivo, J Mol Cell Cardiol, 38, 333, 10.1016/j.yjmcc.2004.11.031 Naldini, 1996, In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector, Science, 272, 263, 10.1126/science.272.5259.263 Qian, 2006, Targeting vascular injury using Hantavirus-pseudotyped lentiviral vectors, Mol Ther, 13, 694, 10.1016/j.ymthe.2005.11.016 Sakuma, 2012, Lentiviral vectors: basic to translational, Biochem J, 443, 603, 10.1042/BJ20120146 Philippe, 2006, Lentiviral vectors with a defective integrase allow efficient and sustained transgene expression in vitro and in vivo, Proc Natl Acad Sci U S A, 103, 17684, 10.1073/pnas.0606197103 Handa, 2008, Adventitial delivery of platelet-derived endothelial cell growth factor gene prevented intimal hyperplasia of vein graft, J Vasc Surg, 48, 1566, 10.1016/j.jvs.2008.07.029 Wang, 2011, Small interfering RNA to c-myc inhibits vein graft restenosis in a rat vein graft model, J Surg Res, 169, e85, 10.1016/j.jss.2011.03.060 Petrofski, 2004, Gene delivery to aortocoronary saphenous vein grafts in a large animal model of intimal hyperplasia, J Thorac Cardiovasc Surg, 127, 27, 10.1016/j.jtcvs.2003.07.032 Petrofski, 2005, A Gβγ inhibitor reduces intimal hyperplasia in aortocoronary saphenous vein grafts, J Thorac Cardiovasc Surg, 130, 1683, 10.1016/j.jtcvs.2005.01.024 Khaleel, 2012, High-pressure distention of the saphenous vein during preparation results in increased markers of inflammation: a potential mechanism for graft failure, Ann Thorac Surg, 93, 552, 10.1016/j.athoracsur.2011.10.035 Mann, 1999, Pressure-mediated oligonucleotide transfection of rat and human cardiovascular tissues, Proc Natl Acad Sci U S A, 96, 6411, 10.1073/pnas.96.11.6411 Vassalli, 1999, A mouse model of arterial gene transfer: antigen-specific immunity is a minor determinant of the early loss of adenovirus-mediated transgene expression, Circ Res, 85, e25, 10.1161/01.RES.85.9.e25 Sugimoto, 2009, Therapeutic approach against intimal hyperplasia of vein grafts through endothelial nitric oxide synthase/nitric oxide (eNOS/NO) and the Rho/Rho-kinase pathway, Surg Today, 39, 459, 10.1007/s00595-008-3912-6 Weaver, 2012, Oxidative stress and vein graft failure: a focus on NADH oxidase, nitric oxide and eicosanoids, Curr Opin Pharmacol, 12, 160, 10.1016/j.coph.2012.01.005 Moncada, 1993, The L-arginine-nitric oxide pathway, N Engl J Med, 329, 2002, 10.1056/NEJM199312303292706 Lamas, 1992, Endothelial nitric oxide synthase: molecular cloning and characterization of a distinct constitutive enzyme isoform, Proc Natl Acad Sci U S A, 89, 6348, 10.1073/pnas.89.14.6348 Gkaliagkousi, 2011, Nitric oxide signalling in the regulation of cardiovascular and platelet function, Front Biosci, 16, 1873, 10.2741/3828 Cable, 1997, Expression and function of a recombinant endothelial nitric oxide synthase gene in porcine coronary arteries, Cardiovasc Res, 35, 553, 10.1016/S0008-6363(97)00161-2 Cable, 1999, The role of gene therapy for intimal hyperplasia of bypass grafts, Circulation, 100, II392, 10.1161/01.CIR.100.suppl_2.II-392 Matsumoto, 1998, Hemagglutinating virus of Japan-liposome-mediated gene transfer of endothelial cell nitric oxide synthase inhibits intimal hyperplasia of canine vein grafts under conditions of poor runoff, J Vasc Surg, 27, 135, 10.1016/S0741-5214(98)70300-3 Ohta, 2002, Intraluminal gene transfer of endothelial cell-nitric oxide synthase suppresses intimal hyperplasia of vein grafts in cholesterol-fed rabbit: a limited biological effect as a result of the loss of medial smooth muscle cells, Surgery, 131, 644, 10.1067/msy.2002.124878 Belton, 2000, Cyclooxygenase-1 and -2-dependent prostacyclin formation in patients with atherosclerosis, Circulation, 102, 840, 10.1161/01.CIR.102.8.840 Crutchley, 1994, Effects of prostacyclin analogs on the synthesis of tissue factor, tumor necrosis factor-alpha and interleukin-1 beta in human monocytic THP-1 cells, J Pharmacol Exp Ther, 271, 446 Hara, 1995, Overexpression of prostacyclin synthase inhibits growth of vascular smooth muscle cells, Biochem Biophys Res Commun, 216, 862, 10.1006/bbrc.1995.2701 Wu, 1997, Regulation of prostaglandin H synthase-1 gene expression, Adv Exp Med Biol, 400A, 121, 10.1007/978-1-4615-5325-0_17 Eichstaedt, 2010, Gene transfer of COX-1 improves lumen size and blood flow in carotid bypass grafts, J Surg Res, 161, 162, 10.1016/j.jss.2008.12.012 Zoldhelyi, 1996, Prevention of arterial thrombosis by adenovirus-mediated transfer of cyclooxygenase gene, Circulation, 93, 10, 10.1161/01.CIR.93.1.10 Zou, 2002, Oxidation of the zinc-thiolate complex and uncoupling of endothelial nitric oxide synthase by peroxynitrite, J Clin Invest, 109, 817, 10.1172/JCI0214442 Hein, 2009, C-reactive protein impairs coronary arteriolar dilation to prostacyclin synthase activation: role of peroxynitrite, J Mol Cell Cardiol, 47, 196, 10.1016/j.yjmcc.2009.04.015 Schmalfuss, 1999, Superoxide anion generation, superoxide dismutase activity, and nitric oxide release in human internal mammary artery and saphenous vein segments, J Cardiovasc Pharmacol Ther, 4, 249, 10.1177/107424849900400406 Hamilton, 1997, Effects of nitric oxide and superoxide on relaxation in human artery and vein, Atherosclerosis, 133, 77, 10.1016/S0021-9150(97)00114-7 Shi, 2001, Oxidative stress and lipid retention in vascular grafts: comparison between venous and arterial conduits, Circulation, 103, 2408, 10.1161/01.CIR.103.19.2408 Huynh, 1999, Reduction of lipid peroxidation with intraoperative superoxide dismutase treatment decreases intimal hyperplasia in experimental vein grafts, J Surg Res, 84, 223, 10.1006/jsre.1999.5647 Turunen, 2006, Extracellular superoxide dismutase with vaccinia virus anti-inflammatory protein 35K or tissue inhibitor of metalloproteinase-1: Combination gene therapy in the treatment of vein graft stenosis in rabbits, Hum Gene Ther, 17, 405, 10.1089/hum.2006.17.405 He, 2006, Delivery of antioxidative enzyme genes protects against ischemia/reperfusion-induced liver injury in mice, Liver Transpl, 12, 1869, 10.1002/lt.21001 Van-Assche, 2011, Gene therapy targeting inflammation in atherosclerosis, Curr Pharm Des, 17, 4210, 10.2174/138161211798764799 Durante, 2010, Targeting heme oxygenase-1 in vascular disease, Curr Drug Targets, 11, 1504, 10.2174/1389450111009011504 Pakala, 2003, Coagulation factor Xa synergistically interacts with serotonin in inducing vascular smooth muscle cell proliferation, Cardiovasc Radiat Med, 4, 69, 10.1016/S1522-1865(03)00144-6 Bretschneider, 2000, Factor Xa acts as a PDGF-independent mitogen in human vascular smooth muscle cells, Thromb Haemost, 84, 499, 10.1055/s-0037-1614051 Pyo, 2004, Mice deficient in tissue factor demonstrate attenuated intimal hyperplasia in response to vascular injury and decreased smooth muscle cell migration, Thromb Haemost, 92, 451, 10.1160/TH04-02-0122 Collen, 1994, Antithrombotic effects and bleeding time prolongation with synthetic platelet GPIIb/IIIa inhibitors in animal models of platelet-mediated thrombosis, Thromb Haemost, 71, 95, 10.1055/s-0038-1642390 Belch, 1980, Low dose heparin in the prevention of deep-vein thrombosis after aortic bifurcation graft surgery, Thromb Haemost, 42, 1429 Gosling, 1999, Arterial flow conditions downregulate thrombomodulin on saphenous vein endothelium, Circulation, 99, 1047, 10.1161/01.CIR.99.8.1047 Kim, 2002, Early loss of thrombomodulin expression impairs vein graft thromboresistance: implications for vein graft failure, Circ Res, 90, 205, 10.1161/hh0202.105097 Tabuchi, 2004, Nonviral in vivo thrombomodulin gene transfer prevents early loss of thromboresistance of grafted veins, Eur J Cardiothorac Surg, 26, 995, 10.1016/j.ejcts.2004.07.028 Torsney, 2004, Thrombosis and neointima formation in vein grafts are inhibited by locally applied aspirin through endothelial protection, Circ Res, 94, 1466, 10.1161/01.RES.0000129570.06647.00 Goldman, 1994, Long-term graft patency (3 years) after coronary artery surgery. Effects of aspirin: results of a VA Cooperative study, Circulation, 89, 1138, 10.1161/01.CIR.89.3.1138 Thomas, 2009, Reduction of early vein graft thrombosis by tissue plasminogen activator gene transfer, Thromb Haemost, 102, 145, 10.1160/TH08-11-0772 Hilfiker, 2001, Enhancement of neointima formation with tissue-type plasminogen activator, J Vasc Surg, 33, 821, 10.1067/mva.2001.112323 Jiang, 2006, Experimental study of tissue-type plasminogen activator gene to prevent vein grafts stenosis, J Huazhong Univ Sci Technolog Med Sci, 26, 314, 10.1007/BF02829561 Cerletti, 2012, Platelet-leukocyte interactions in thrombosis, Thromb Res, 129, 263, 10.1016/j.thromres.2011.10.010 Pober, 2012, Participation of blood vessel cells in human adaptive immune responses, Trends Immunol, 33, 49, 10.1016/j.it.2011.09.006 Vestweber, 2007, Adhesion and signaling molecules controlling the transmigration of leukocytes through endothelium, Immunol Rev, 218, 178, 10.1111/j.1600-065X.2007.00533.x Williams, 2011, Emerging mechanisms of neutrophil recruitment across endothelium, Trends Immunol, 32, 461, 10.1016/j.it.2011.06.009 Wolff, 2004, Macrophage depletion reduces monocyte chemotactic protein-1 and transforming growth factor-beta1 in healing rat vein grafts, J Vasc Surg, 39, 878, 10.1016/j.jvs.2003.11.039 Stark, 1997, Monocyte chemotactic protein-1 expression is associated with the development of vein graft intimal hyperplasia, Arterioscler Thromb Vasc Biol, 17, 1614, 10.1161/01.ATV.17.8.1614 Cipollone, 2001, Elevated circulating levels of monocyte chemoattractant protein-1 in patients with restenosis after coronary angioplasty, Arterioscler Thromb Vasc Biol, 21, 327, 10.1161/01.ATV.21.3.327 Hokimoto, 2002, Increased expression of monocyte chemoattractant protein-1 in atherectomy specimens from patients with restenosis after percutaneous transluminal coronary angioplasty, Circ J, 66, 114, 10.1253/circj.66.114 Zhang, 1994, Structure/activity analysis of human monocyte chemoattractant protein-1 (MCP-1) by mutagenesis. Identification of a mutated protein that inhibits MCP-1-mediated monocyte chemotaxis, J Biol Chem, 269, 15918, 10.1016/S0021-9258(17)40768-X Zhang, 1995, A dominant negative inhibitor indicates that monocyte chemoattractant protein 1 functions as a dimer, Mol Cell Biol, 15, 4851, 10.1128/MCB.15.9.4851 Schepers, 2006, Anti-MCP-1 gene therapy inhibits vascular smooth muscle cells proliferation and attenuates vein graft thickening both in vitro and in vivo, Arterioscler Thromb Vasc Biol, 26, 2063, 10.1161/01.ATV.0000235694.69719.e2 Tatewaki, 2007, Blockade of monocyte chemoattractant protein-1 by adenoviral gene transfer inhibits experimental vein graft neointimal formation, J Vasc Surg, 45, 1236, 10.1016/j.jvs.2007.01.066 Eefting, 2009, Local lentiviral short hairpin RNA silencing of CCR2 inhibits vein graft thickening in hypercholesterolemic apolipoprotein E3-Leiden mice, J Vasc Surg, 50, 152, 10.1016/j.jvs.2009.03.027 Pamukcu, 2011, The nuclear factor–κ B pathway in atherosclerosis: a potential therapeutic target for atherothrombotic vascular disease, Thromb Res, 128, 117, 10.1016/j.thromres.2011.03.025 Shintani, 2002, Intraoperative transfection of vein grafts with the NFκB decoy in a canine aortocoronary bypass model: a strategy to attenuate intimal hyperplasia, Ann Thorac Surg, 74, 1132, 10.1016/S0003-4975(02)03921-8 Rossi, 2000, The biology of chemokines and their receptors, Annu Rev Immunol, 18, 217, 10.1146/annurev.immunol.18.1.217 Alcami, 1998, Blockade of chemokine activity by a soluble chemokine binding protein from vaccinia virus, J Immunol, 160, 624, 10.4049/jimmunol.160.2.624 Bursill, 2003, Adenoviral-mediated delivery of a viral chemokine binding protein blocks CC-chemokine activity in vitro and in vivo, Immunobiology, 207, 187, 10.1078/0171-2985-00228 Bursill, 2004, Broad-spectrum CC-chemokine blockade by gene transfer inhibits macrophage recruitment and atherosclerotic plaque formation in apolipoprotein E-knockout mice, Circulation, 110, 2460, 10.1161/01.CIR.0000145122.58420.CO Ali, 2005, Gene transfer of a broad spectrum CC-chemokine inhibitor reduces vein graft atherosclerosis in apolipoprotein E-knockout mice, Circulation, 112, I235, 10.1161/CIRCULATIONAHA.104.526129 Puhakka, 2005, Effects of vaccinia virus anti-inflammatory protein 35K and TIMP-1 gene transfers on vein graft stenosis in rabbits, In Vivo, 19, 515 Bursill, 2006, Membrane-bound CC chemokine inhibitor 35K provides localized inhibition of CC chemokine activity in vitro and in vivo, J Immunol, 177, 5567, 10.4049/jimmunol.177.8.5567 Gotoh, 2004, E-selectin blockade decreases adventitial inflammation and attenuates intimal hyperplasia in rat carotid arteries after balloon injury, Arterioscler Thromb Vasc Biol, 24, 2063, 10.1161/01.ATV.0000145942.31404.20 Jabs, 2007, Sequential patterns of chemokine- and chemokine receptor-synthesis following vessel wall injury in porcine coronary arteries, Atherosclerosis, 192, 75, 10.1016/j.atherosclerosis.2006.05.050 Okamoto, 2001, Perivascular inflammation after balloon angioplasty of porcine coronary arteries, Circulation, 104, 2228, 10.1161/hc4301.097195 Siow, 2007, Adventitial growth factor signalling and vascular remodelling: potential of perivascular gene transfer from the outside-in, Cardiovasc Res, 75, 659, 10.1016/j.cardiores.2007.06.007 Newby, 2005, Dual role of matrix metalloproteinases (matrixins) in intimal thickening and atherosclerotic plaque rupture, Physiol Rev, 85, 1, 10.1152/physrev.00048.2003 George, 2000, Inhibition of Late Vein Graft Neointima Formation in Human and Porcine Models by Adenovirus-Mediated Overexpression of Tissue Inhibitor of Metalloproteinase-3, Circulation, 101, 296, 10.1161/01.CIR.101.3.296 George, 2011, Sustained reduction of vein graft neointima formation by ex vivo TIMP-3 gene therapy, Circulation, 124, S135, 10.1161/CIRCULATIONAHA.110.012732 Wilson, 1993, Mechanical strain induces growth of vascular smooth muscle cells via autocrine action of PDGF, J Cell Biol, 123, 741, 10.1083/jcb.123.3.741 Dashwood, 2007, Surgical damage of the saphenous vein and graft patency, J Thorac Cardiovasc Surg, 133, 274, 10.1016/j.jtcvs.2006.09.029 Mann, 1995, Genetic engineering of vein grafts resistant to atherosclerosis, Proc Natl Acad Sci U S A, 92, 4502, 10.1073/pnas.92.10.4502 Huang, 2002, Inhibition of vascular smooth muscle cell proliferation, migration, and survival by the tumor suppressor protein PTEN, Arterioscler Thromb Vasc Biol, 22, 745, 10.1161/01.ATV.0000016358.05294.8D Huang, 2005, Adenovirus-mediated intra-arterial delivery of PTEN inhibits neointimal hyperplasia, Arterioscler Thromb Vasc Biol, 25, 354, 10.1161/01.ATV.0000151619.54108.a5 Cantley, 2002, The phosphoinositide 3-kinase pathway, Science, 296, 1655, 10.1126/science.296.5573.1655 Rameh, 1999, The role of phosphoinositide 3-kinase lipid products in cell function, J Biol Chem, 274, 8347, 10.1074/jbc.274.13.8347 Sousa, 2001, Sustained suppression of neointimal proliferation by sirolimus-eluting stents: one-year angiographic and intravascular ultrasound follow-up, Circulation, 104, 2007, 10.1161/hc4201.098056 Sousa, 2003, Sirolimus-eluting stent for the treatment of in-stent restenosis: a quantitative coronary angiography and three-dimensional intravascular ultrasound study, Circulation, 107, 24, 10.1161/01.CIR.0000047063.22006.41 Gingras, 2001, Regulation of translation initiation by FRAP/mTOR, Genes Dev, 15, 807, 10.1101/gad.887201 Maehama, 1998, The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate, J Biol Chem, 273, 13375, 10.1074/jbc.273.22.13375 Weinberg, 1995, The retinoblastoma protein and cell cycle control, Cell, 81, 323, 10.1016/0092-8674(95)90385-2 Ehsan, 2001, Long-term stabilization of vein graft wall architecture and prolonged resistance to experimental atherosclerosis after E2F decoy oligonucleotide gene therapy, J Thorac Cardiovasc Surg, 121, 714, 10.1067/mtc.2001.111204 Ehsan, 2002, Endothelial healing in vein grafts: proliferative burst unimpaired by genetic therapy of neointimal disease, Circulation, 105, 1686, 10.1161/01.CIR.0000013775.02396.93 Mann, 1997, Cell cycle inhibition preserves endothelial function in genetically engineered rabbit vein grafts, J Clin Invest, 99, 1295, 10.1172/JCI119288 Mann, 1997, Vein graft gene therapy using E2F decoy oligonucleotides: target gene inhibition in human veins and long term resistance to atherosclerosis in rabbits, Surg Forum, 242 2001, Late-Breaking Clinical Trial Abstracts, Circulation, 104, 1b Conte, 2006, Results of PREVENT III: a multicenter, randomized trial of edifoligide for the prevention of vein graft failure in lower extremity bypass surgery, J Vasc Surg, 43, 742, 10.1016/j.jvs.2005.12.058 Attwooll, 2004, The E2F family: specific functions and overlapping interests, EMBO J, 23, 4709, 10.1038/sj.emboj.7600481 Chong, 2009, E2f1-3 switch from activators in progenitor cells to repressors in differentiating cells, Nature, 462, 930, 10.1038/nature08677 Motwani, 1998, Aortocoronary saphenous vein graft disease: pathogenesis, predisposition, and prevention, Circulation, 97, 916, 10.1161/01.CIR.97.9.916 Zhang, 2004, Graft-extrinsic cells predominate in vein graft arterialization, Arterioscler Thromb Vasc Biol, 24, 470, 10.1161/01.ATV.0000116865.98067.31 Fogelstrand, 2005, Reduced neointima in vein grafts following a blockage of cell recruitment from the vein and the surrounding tissue, Cardiovasc Res, 67, 326, 10.1016/j.cardiores.2005.03.027 Lopes, 2012, Relationship between vein graft failure and subsequent clinical outcomes after coronary artery bypass surgery, Circulation, 125, 749, 10.1161/CIRCULATIONAHA.111.040311 Owens, 2007, Elevated C-reactive protein levels are associated with postoperative events in patients undergoing lower extremity vein bypass surgery, J Vasc Surg, 45, 2, 10.1016/j.jvs.2006.08.048 Thomas, 2012, Animal models for studying vein graft failure and therapeutic interventions, Curr Opin Pharmacol, 12, 121, 10.1016/j.coph.2012.01.002 Kuliszewski, 2011, Vascular gene transfer of SDF-1 promotes endothelial progenitor cell engraftment and enhances angiogenesis in ischemic muscle, Mol Ther, 19, 895, 10.1038/mt.2011.18